Prognostic Role of Topoisomerase-IIα in Advanced Ovarian Cancer Patients
Author Information
Author(s): Ferrandina G, Petrillo M, Carbone A, Zannoni G, Martinelli E, Prisco M, Pignata S, Breda E, Savarese A, Scambia G
Primary Institution: Catholic University, Campobasso and Rome, Italy
Hypothesis
The study aims to investigate the prognostic value of TOPO-IIα expression in advanced ovarian cancer patients.
Conclusion
High levels of TOPO-IIα expression are associated with a shorter overall survival in platinum-resistant ovarian cancer patients.
Supporting Evidence
- TOPO-IIα immunoreaction was observed in 72.9% of cases.
- High TOPO-IIα expression was associated with a median overall survival of 35 months compared to 54 months for low expression.
- Statistically significant associations were found between TOPO-IIα levels and the risk of death.
Takeaway
This study found that ovarian cancer patients with high levels of a protein called TOPO-IIα tend to have worse outcomes, especially if their cancer is resistant to standard treatments.
Methodology
The study used immunohistochemistry to assess TOPO-IIα expression in tumor samples from 96 advanced ovarian cancer patients.
Potential Biases
Potential biases may arise from the lack of a defined scoring system for TOPO-IIα expression.
Limitations
The study is limited to a single institution and may not be generalizable to all ovarian cancer patients.
Participant Demographics
Median age was 60 years, with 80.2% of patients in stage III and 19.8% in stage IV.
Statistical Information
P-Value
0.0101
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website